Cancer-related cognitive impairment in breast cancer patients exposed to multi-agent chemotherapy regimens is associated with the apolipoprotein E4 (APOE4) allele. However, it is difficult to determine the effects of specific agents on cognitive impairment in human studies. We describe the development of a human APOE knock-in congenic C57BL/6J mouse model to study cancerrelated cognitive impairment. Female APOE3 and APOE4 homozygous mice were either left untreated or treated with the most commonly used breast cancer therapeutic agent, doxorubicin. APOE3 and APOE4 mice had similar behaviors in exploratory and anxiety assays, which were affected transiently by doxorubicin treatment. Spatial learning and memory were measured in a Barnes maze: after 4 days of training, control APOE3 and APOE4 mice were able to escape with similar latencies. In contrast, doxorubicin-treated APOE4 mice had markedly impaired learning compared to doxorubicin-treated APOE3 mice at all time points. Voxel-based morphometry of magnetic resonance images revealed that doxorubicin treatment caused significant changes in the cortex and hippocampus of in both APOE3 and APOE4 mouse brains, but the differences were significantly greater in the APOE4 brains. The results indicate that doxorubicin-exposed APOE4 mice recapitulate key aspects of human cancer-related cognitive impairment. These data support the usefulness of this novel preclinical model for future elucidation of the genetic and molecular interactions of APOE genotype with chemotherapy; this model can also allow extension to prospective studies of older mice to study these interactions in the context of aging.
Introduction
Cancer and neurodegenerative diseases account for the majority of morbidity, mortality, and healthcare costs in the USA among older individuals (Dewey and Saz 2001; Mariotto et al. 2011) . There are presently approximately 15.5 million cancer survivors living in the USA (Bluethmann et al. 2016; Miller et al. 2016; Rowland and Bellizzi 2014) , and two-thirds of these survivors are aged 65 and older (Mariotto et al. 2011) . The process of aging places these older cancer survivors at risk of neurodegenerative disease (Mandelblatt et al. 2014b) and its associated cognitive impact.
Human and animal studies suggest that cancer chemotherapeutic agents can lead to alterations in biomarkers of aging (Sanoff et al. 2014 ), cause cognitive decline (Kesler and Blayney 2016; Sanoff et al. 2014) , and result in brain atrophy that mimics degenerative age-related changes (Kesler and Blayney 2016; Mandelblatt et al. 2013; 2014b; Nudelman et al. 2016) . Hence, older cancer survivors are likely to be particularly vulnerable to experiencing cognitive decline as a result of age and cancer and its treatments.
Recent data from our group and that of others have shown that having an E4 allele of the APOE (apolipoprotein E) gene is a risk factor for chemotherapy-related cognitive decline (Ahles et al. 2010 (Ahles et al. , 2014 Mandelblatt et al. 2018 ). This finding is highly relevant given that the APOE4 allele is present in approximately 70 million Americans (about 25% of the population), affects normal brain function and structure, and is the strongest genetic risk factor for Alzheimer's disease (Raber et al. 2004) . The APOE4 allele also affects brain inflammatory processes, plasticity and repair mechanisms important in aging and neurodegeneration (Heppner et al. 2015; Malik et al. 2015; Namjoshi et al. 2013; Zhong et al. 2016) .
Longitudinal studies in older cancer survivor populations are useful to investigate the complex relationships between genetic factors, cancer and its treatment, and aging with potential molecular and pathophysiological mechanisms of cognitive decline. However, it is unlikely that sufficiently large cohorts of patients can be accrued to define individual drugspecific effects as well as the mechanistic underpinnings of these interactions, given the numbers and combinations of therapeutic agents (Seigers et al. 2015) , the effects of different lifestyle factors, and the long follow-up period needed to define aging effects on cognitive behavior and brain structure and function. In such a situation, preclinical animal models that are built upon human observations can be useful to accelerate discovery (Seigers et al. 2015) .
Prior studies of preclinical models of cancer-related cognitive decline have identified adverse effects of doxorubicin on measures of memory (Seigers et al. 2015) , hippocampal neurogenesis (Acharya et al. 2015; Christie et al. 2012; Wigmore 2013) , hippocampal volumes (Seigers and Fardell 2011; Seigers et al. 2016) , oxidative stress (Keeney et al. 2018) , and inflammation (Tangpong et al. 2007; Tangpong et al. 2011) . However, only one of these studies included older animals (Dubois et al. 2014) , and none have assessed longitudinal changes in female mice, or considered genetic risk factors related to cognitive decline.
We previously described the analysis of several brain and behavioral phenotypes of a human APOE knock-in mouse model that supports the normal expression and regulation of the human APOE3 and APOE4 alleles (Sullivan et al. 2004 ). The APOE4 mice have significant deficits in neuronal structure and cognition compared to APOE3 mice, as well as higher levels of pro-inflammatory cytokines in response to various brain insults (DiBattista et al., 2016a, b; Rodriguez et al. 2013; Rodriguez et al. 2014; Tai et al. 2015; Zhao et al. 2014; Zhou et al. 2015; Zhu et al. 2012) . Thus, this mouse model is an excellent preclinical option for studying the phenotypes of normal individuals possessing the APOE3 and APOE4 alleles.
In this study, we describe the development of a biologically and clinically relevant mouse model of cancer-related cognitive decline with the goal of better defining the effects of specific APOE alleles in this disorder. We identify APOE genotype related differences among untreated mice and mice exposed to doxorubicin, focusing on spatial learning behavior and on hippocampal and cortical volumes. These domains are particularly relevant to effects seen in humans experiencing cognitive impairment after chemotherapy. Data from this new mouse model will ultimately help elucidate the molecular mechanisms by which specific cancer treatments interact with APOE4 in the context of aging to impact cognitive function.
Methods

Ethics Statement
This study was conducted in accordance with ethical standards and relevant national and international guidelines for animal welfare, including the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures and handling of the animals were also performed according to protocols approved by the Georgetown University Medical Center Institutional Animal Care and Use Committee.
Study Design
This preclinical study followed the recent recommendations of the International Cognition and Cancer Task Force for harmonization of preclinical studies (Winocur et al. 2018) . We tested for differences in behavior and brain structure by APOE genotype in untreated mice and in doxorubicin-treated mice. Doxorubicin is the most commonly used chemotherapeutic agent used in breast cancer and one of the most frequently implicated in cancer-related cognitive decline in human (Kesler and Blayney 2016) and animal studies (Seigers et al. 2016) . We compared behaviors in untreated mice at one time point, and in doxorubicin-treated mice at time points relative to a single exposure to doxorubicin: pre-exposure, and 1and 6 weeks after exposure. Mice were euthanized after behavioral testing and whole brains were prepared for imaging.
Animal Population
Human APOE3 (n = 18) and APOE4 (n = 21) knock-in C57BL/6J female mice (Jackson Laboratories, Inc., Bar Harbor, ME) were maintained at Georgetown University. Congenic C57BL/6J mice are most commonly used in studies of cognition based on their intermediate phenotype in spontaneous behavior and good learning skills (Brooks et al. 2005; Loos et al. 2014; Seigers et al. 2015) . As we were testing a chemotherapeutic agent used for breast cancer, we limited our experiment to females (Bimonte-Nelson et al. 2003) . The animals were bred as homozygotes. The APOE3 mice are equivalent to humans with the APOE3.3 genotype (64% of the US population), and the APOE4 mice are equivalent to humans with the APOE4.4 genotype (2% of the US population) (Ward et al. 2012) . The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (Raber et al. 2004) . Studies with doxorubicin were initiated in mice at approximately 14 weeks of age and completed at 21 weeks of age; control mice were analyzed at 22 to 25 weeks of age.
Staff involved in breeding, genotype verification, tagging, colony maintenance, and chemotherapy administration were separate from those involved in the behavioral testing, imaging, and analyses. The latter personnel were blinded to genotype and chemotherapy exposure status. Mice were housed in cages with littermates and were kept on a 12-h light/dark cycle and had ad libitum access to water and rodent chow.
Treatment
Mice were weighed weekly throughout the experiment. Doxorubicin (10 mg/kg; Abcam, PLC, Cambridge, UK) was prepared in DMSO under sterile conditions for a single tail vein injection volume of 100 μL. The control animals were left untreated. The health of each animal, based on weight, general appearance, level of activity, and signs of inflammation due to injection, was checked daily. Animals that experienced tail erythema had antibiotic ointment applied three times per week until the condition improved. The open field and elevated plus tests were performed 1 week prior to treatment, and 1 and 6 weeks post-treatment.
Measures and Testing Procedures
Weight, general and neurological behaviors, and ex vivo histological organ changes were used as measures of chemotherapy toxicity. The outcome measures included behavioral assays and MRI-quantified cerebral morphological alterations.
Behavioral Assays
Open Field Test An open field measuring 45 cm × 45 cm was used 1 week prior to treatment and 1 and 6 weeks posttreatment (or contemporaneously for controls) to measure general behavior, including anxiety, exploration, and locomotion. The field was illuminated evenly at 100 lx by overhead lighting in a quiet room with no external cues. Animals were positioned in the center of the open field and allowed to explore the apparatus for 5 min. Overall locomotor activity (path length) was recorded by an overhead camera and analyzed using the Anymaze behavioral tracking package (Stoelting Co., Wood Dale, IL). The number of animal rears was also recorded to measure general vigilance and exploratory drive.
Elevated Plus Maze The elevated plus maze was used as a measure of anxiety. The maze, with arms measuring 30 cm in length and 30 cm in height, was placed in a quiet room and illuminated evenly at 100 lx by overhead lighting. The mice were placed in the center of the maze facing an open arm and allowed to explore the maze for 5 min. The duration of time spent in the open arms was recorded by an overhead camcorder and data was analyzed using Anymaze software suite. Time in exposed arms of the maze indicates lower levels of anxiety.
Barnes Maze The Barnes maze (San Diego Instruments Inc., San Diego, CA) was used to measure spatial learning and memory. Given the known strong practice effects, the Barnes maze was used once, during the fifth week after treatment, or during the contemporaneous age for controls. To minimize variability, all testing was done by the same investigator at the same time of day, and on the same apparatus.
The maze was placed in the center of a room with four extra-maze cues. Using established Barnes maze protocols (Rosenfeld and Ferguson 2014) , four lights provided 150 lx of illumination to the maze and an overhead radio played 75 dB of white noise in order to provide aversive stimuli during trials. Out of 20 possible escape holes, one escape was randomly chosen and fitted with a 10 cm × 4 cm × 4 cm escape container. All other escape locations contained shallow decoy escape boxes. The mice were placed in the center of the maze under a darkened canopy for 10 s prior to each trial. During the habituation phase, the mice were allowed to explore the maze for a single 180-s trial and were gently guided to the escape hole if they failed to locate it before the end of the trial. The mice repeated these trials four times per day over the next 4 days, with trials spaced 15 min apart. The time required to learn the location of the escape hole for each trial (latency, in seconds) was used to measure spatial learning.
To examine whether the mice were using external spatial cues to locate the hole, a blinded observer also categorized the learning strategy of each mouse (random, serial, or direct) on each training day. A direct strategy was defined as one in which the mouse moved directly into the target quadrant, crossed the maze center less than twice, and made three or fewer incorrect nose pokes at a decoy hole (Rosenfeld and Ferguson 2014) . The target hole, each decoy hole, and the maze itself were cleaned with a mild soap and water solution between each trial in order to eliminate olfactory cues.
A single probe trial was conducted 72 h after the above final testing trial, during which the previous escape hole was replaced with a twentieth decoy escape to test spatial memory. This trial was stopped once the animal entered the correct decoy escape location or after 180 s. Animal behavior (time to find the former escape hole location) was recorded by an overhead camcorder and analyzed using Anymaze.
Magnetic Resonance Imaging
After completion of all behavioral testing, mice were euthanized using a CO 2 chamber and transcardially perfused with 50 mL of 10% neutral buffered formalin. For the control animals, six APOE3 and six APOE4 whole brains were harvested for magnetic resonance imaging (MRI). For the treated groups, the whole brains from approximately 50% of the animals of each genotype (five APOE3 and six APOE4) were extracted and embedded in 3% agar in PBS for ex vivo MRI, as described previously (Lee et al. 2018) . Three-dimensional ex vivo MRI was performed in order to analyze differences in regional brain anatomy using voxel-based morphometry (VBM) (Ashburner and Friston 2000) . Briefly, MRI was performed in the GeorgetownLombardi Preclinical Imaging Research Laboratory in a 7-T Bruker spectrometer (Bruker Biospin, Ettlingen, Germany) running Paravision 5.1 software, with a 32-mm mouse brain volume coil. A 3-D rapid acquisition with relaxation enhancement (RARE) T2-weighted sequence was used to assess anatomical changes with the following: repetition time = 2500 ms, effective echo time = 36 ms, RARE factor = 12, flip angle = 90 degrees, field of view = 17.5 × 17.5 × 20 mm 
Voxel-Based Morphometry
For the analysis of the 3-D MRI datasets, the 2dseq raw images were first converted to Bruker Dicom files, exported and converted to NIfTI format files using MRIcron software. Images were skull-stripped using MIPAV 7.1.1 software. The images were aligned to the SPMMouse mouse brain template via affine transformation with 12 parameters (translations, shears, rotation, and scale factors in three dimensions) using FSL (FMRIB Software Library, Oxford, UK). Based on the unified segmentation algorithm, each image was segmented into gray matter (GM), white matter using SPMMouse. The warped modulated GM maps were smoothed with a 0.5-mm FWHM Gaussian kernel.
These data were used to test for group-wise differences in the GM maps across the whole brain with SPMMouse toolbox by performing a voxel-by-voxel two-sample t test and f test. Whole brain analysis was reformed with a significance level of p < 0.03, uncorrected for multiple comparisons.
Data Analysis
Bivariate analyses were used, including independent sample t tests, one-way ANOVA, and Fisher's exact tests to compare the mice by genotype and exposure group with respect to baseline pre-exposure and post-exposure behaviors; a p value of < 0.05 was considered statistically significant. Doxorubicin-treated APOE3 and APOE4 mice were analyzed behaviorally at a separate time than the untreated controls, so direct statistical comparisons only examined the effects of APOE genotype in doxorubicin-treated mice or of APOE genotype in control mice groups. In contrast, VBM statistical analyses were conducted both within and between groups, due to the low variability of this assay over time. Analysis of behavioral statistics and figure generation of these data was performed using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA).
Results
The average weight of the mice was 18.5 g (SD 1.3 g) and did not vary by APOE genotype. After a single injection of doxorubicin, all the treated mice maintained their body weight or showed a small weight loss (< 10% of body weight). There was no significant weight difference between untreated APOE3 or APOE4 control mice before or after behavioral testing. Four of the treated mice (two APOE3, two APOE4) displayed local irritation surrounding the tail vein injection site. There were no treatment-related deaths.
There were no differences in exploration and anxiety by genotype in control mice: APOE4 mice displayed a similar drive in exploring a novel environment (open field) as their APOE3 counterparts, based on the total distance traveled within the field (Fig. 1a) and rearing events in the same open field (Fig. 1c) . Likewise, there were no significant differences observed between APOE genotypes in a test of rodent anxiety (elevated plus; Fig. 1e ).
There were no differences in exploration and anxiety by genotype at baseline in the treatment group (Fig. 1 b, d, f) . One week after treatment with doxorubicin, both APOE3 and APOE4 mice showed a significantly decreased willingness to explore the open field (both distance traveled and rearing) compared to their pre-exposure behaviors. By 6 weeks posttreatment, APOE3 mice returned to their pre-test exploratory levels, whereas APOE4 mice maintained a significant reduction compared to their pre-treatment behaviors (Fig. 1b, d , p < .05). There were no differences in post-treatment anxiety by genotype as measured by time spent in the open arms of the elevated plus maze (Fig. 1f) .
Cognitive Behavior Outcomes
Controls
There were significant differences by APOE genotypes in spatial learning and memory in control mice. During each training day in the learning phase, APOE4 mice displayed significantly poorer spatial learning (i.e., the ability to locate the target escape hole in the Barnes maze) when compared to APOE3 mice (p < 0.01). This difference decreased by training day 4, but nonetheless remained significant (APOE3 mice: 11 s; APOE4 mice: 22 s, p < 0.01) (Fig. 2a) . A 72-h probe trial, designed to measure long-term retention of the target hole location, likewise revealed a significant difference in the ability to locate the target hole between APOE genotypes (p < 0.01) (Fig. 2b) . Analysis of the search strategies showed that the proportion of mice using a direct strategy in any given trial, indicating accurate retention and use of the external spatial cues, increased as animals learned the maze from training day 1 to day 4 (Fig. 3a) . Control APOE3 mice showed higher use of a direct strategy compared to control APOE4 mice, although, on the final training day, there was no significant difference between APOE genotypes.
Chemotherapy-Exposed
Five weeks post-exposure, doxorubicin-treated APOE4 mice, compared to doxorubicin-treated APOE3 mice, took a significantly longer time to locate the target hole (latency) on each of the four training days (16 total trials; Fig. 2c ). By training day 4, the APOE3 mice located the target hole in an average of 16 s, significantly less than the nearly 100 s for the APOE4 mice (p < 0.001). Differences between the chemotherapytreated APOE3 and APOE4 mice were observed as early as the first training day; treated APOE3 mice took less time to locate the target hole compared to treated APOE4 mice on all but the first trial (Fig. 2c, inset) . In the 72-h probe trial, treated APOE4 mice exhibited significantly greater time than treated APOE3 mice to locate and enter the escape target hole 3 days after the last training day, as expected given their poor learning over the training days (p < 0.01, Fig. 2d ). The proportion of doxorubicin-treated APOE3 mice using a direct strategy to (panels a, c, e) , or for treated APOE mice 1 week prior to exposure to doxorubicin, 1 week post-exposure, and 6 weeks post-exposure (panels b, d, f). Doxorubicin-naïve APOE mice had no significant differences across APOE genotypes in locomotion, rearing, or anxiety between genotypes. Both treated APOE genotypes showed significantly decreased locomotion and exploration 1 week post-exposure, while only the APOE4 mice continued to show significant reductions from pre-treatment levels at 6 weeks. There were no effects of doxorubicin on anxietyrelated behavior. APOE3, n = 7; APOE4, n = 8; APOE3 + dox, n = 11; APOE4 + dox, n = 13. Measures are mean values ± SEM. 1-way ANOVA with Tukey's HSD post-hoc correction for multiple comparisons. **p < .01 ***p < .001 vs. pretreatment Fig. 2 Barnes maze spatial learning and memory in untreated and doxorubicin-exposed APOE3 and APOE4 mice. Performance of untreated animals (panel a) and doxorubicin-exposed animals (panel c) throughout Barnes maze training days 1-4 (TD1-4) with inset for the four trials (T1-4) on training day 1. Reduction in latency to the target hole is recorded as a measure of training in this spatial learning task. Compared to APOE4 mice, APOE3 mice showed significantly shorter latencies during all four training days and during individual trials on training day 1, in both untreated (a) and treated (c) cohorts. A 72-h probe trial for untreated animals (panel b) and doxorubicin-exposed animals (panel d) showed lower latency for APOE3 mice compared to APOE4 mice, irrespective of treatment. Data are shown as mean latency to complete the task ± SEM. Barnes maze: 1-way ANOVA with Tukey's HSD posthoc correction for multiple comparisons. 72-h probe trial: twotailed student's t test. (APOE3, n = 7; APOE4, n = 8; APOE3 + dox, n = 11; APOE4 + dox, n = 13) **p < .01 ***p < .001 APOE4 vs. APOE3 mice on the same trial or training day) Fig. 3 Barnes maze strategies to locate the escape target. The strategy employed by each mouse to locate the target hole in each trial was recorded during training. a On the first training day (TD1), both untreated APOE genotypes used indirect exploration strategies (random activity or serial exploration of holes) to locate the escape hole. By the fourth training day (TD4), both APOE3 and APOE4 mice were employing a direct approach to the target hole in similar proportions (71% vs. 62%, respectively). b For doxorubicin-exposed animals, both APOE genotypes on the first TD used largely indirect search strategies. On TD3 and TD4, the APOE3 mice treated with doxorubicin (APOE3 + dox) used a direct method to locate the escape hole more often than the APOE4 + dox mice (52% vs. 29%). There was a significant effect of APOE genotype in search strategy on TD3 for doxorubicin-naïve mice (Fisher's exact test of independence, p = 0.01) and a significant effect of APOE genotype in search strategy on TD3 and TD4 for doxorubicinexposed mice (*p = 0.01 and p = 0.03, respectively) locate the hole was significantly greater than APOE4 mice on the third and fourth training days (p < 0.05, Fig. 3b ).
Control and doxorubicin-treated APOE3 mice showed similar patterns of spatial learning from training days 1 to 4 (Table 1) . Control and doxorubicin-treated APOE4 mice showed decreased spatial learning ability in the Barnes maze when compared to the corresponding APOE3 mice. When expressed as a percentage of total allowed time taken to enter the target hole (180 s), both unexposed and doxorubicintreated APOE3 treatment groups were able to enter the target hole relatively quickly at the end of the test compared to the beginning of the test (7% and 9% of the time, respectively). Likewise, unexposed APOE4 mice were able to locate and enter the target hole within 12% of their total allotted time on training day 4. However, APOE4 mice exposed to doxorubicin showed significantly longer latencies to locate and enter the correct escape hole, with 55% of the allotted trial time to escape the Barnes maze, even by day four (Table 1 ).
Brain Structure
In order to investigate morphological cerebral alterations associated with chemotherapy, we performed anatomical MRI of both unexposed and doxorubicin-treated APOE3 and APOE4 mice and conducted whole-brain analysis using voxel-based morphometry. Group comparisons of GM volume revealed that, compared to control APOE3 mice, control APOE4 mice had several significantly smaller gray matter volumes bilaterally, including dorsal portions of the hippocampus and regions of the striatum (Fig. 4a, b) . Furthermore, compared to doxorubicin-exposed APOE3 mice, the doxorubicin-exposed APOE4 mice had significantly smaller gray matter volumes bilaterally in the dorsal and ventral hippocampus, the striatum, and the piriform cortex as well as the lateral geniculate nucleus (Fig. 4c, d) . Interestingly, these comparisons across APOE genotypes showed larger affected hippocampal regions in doxorubicin-treated APOE4 mice (Fig. 4b, d ).
These observations led us to directly test the effects of doxorubicin treatment on APOE3 mice and on APOE4 mice, by comparing the doxorubicin-exposed brains to the unexposed brains (Fig. 5) . Based on the VBM analysis of 3-D whole brain image datasets, we found that after doxorubicin treatment, the APOE3 mice showed significant differences in gray matter bilaterally in the frontal cortex and throughout the hippocampus (Fig. 5a, c) . Importantly, the APOE4 mice showed a very similar pattern of gray matter alterations compared to the APOE3 mice. These alterations for the APOE4 mice were markedly stronger than for the APOE3 mice (Fig. 5b, d ). These observations are consistent with Fig. 4d showing differences in hippocampal volumes in the doxorubicin-treated APOE4 mice compared to the doxorubicin-treated APOE3 mice.
Discussion
Several prominent genetic factors predispose individuals to different types of neurodegenerative diseases; recent studies have suggested that the same may be true for cognitive decline after cancer chemotherapy (Snyder et al. 2017) . Here, we report the first study to apply a human APOE knock-in rodent model to examine the possible interactions of the APOE genotype with chemotherapeutic agents and the effect of this association on cognitive behavior and brain structure. We found that APOE4 mice treated with doxorubicin, a standard of care breast cancer chemotherapy agent, exhibited an impairment of behaviors and alterations in brain structure compared to their APOE3 counterparts and untreated control APOE4 mice. These results suggest that this preclinical model could be further developed into a novel translational in vivo platform for defining the mechanisms of chemotherapyrelated cognitive impairment using additional chemotherapeutic agents, both as single agents and in combination treatments, recapitulating regimens frequently used in the clinic. In addition, this model provides the experimental foundation for directly assessing the combined effects of aging and APOE status on chemotherapy-induced cognitive impairment.
In past preclinical studies, doxorubicin (Salas-Ramirez et al. 2015) and other breast cancer chemotherapy agents (Foley et al. 2008; Yang et al. 2010 ) caused decrements in cognitive behaviors (Seigers et al. 2015) and adverse effects on brain structure or growth in mice (Acharya et al. 2015; Christie et al. 2012; Seigers and Fardell 2011; Seigers et al. 2016; Wigmore 2013) . For example, Seigers et al. (2015) found impairment in spatial memory in male C57BL/6J mice 2 weeks after doxorubicin treatment with a similar dose to that used in our study. Our results are consistent with these past studies, despite differences in the experimental design and genetic background, and extend these results to suggest a gene-treatment interaction in effects on cognition.
The APOE4 allele is the best characterized genetic factor to date associated with an increased risk of cancer-related cognitive decline (Ahles et al. 2014; Ahles et al. 2003; Mandelblatt et al. 2014b ). There are three major APOE alleles, with APOE4 being associated with an increased risk and earlier onset of Alzheimer's disease (Liu et al. 2013) . APOE3 is the most common allele, and thus, the APOE3 knock-in mice represent an accurate population-based control group for our preclinical model. Importantly, neither APOE3 nor APOE4 mice develop the brain lesions associated with Alzheimer's disease (amyloid plaques and neurofibrillary tangles), and therefore, they are excellent models of patients without frank neurodegeneration, which would be a confounding factor for studies of behavior and brain atrophy. Reduced hippocampal volume has been observed in human neuroimaging studies of both cancer-related cognitive decline and Alzheimer's disease (Nudelman et al. 2016; Saykin et al. 2013; Schuff et al. 2009) . In this study, we compared the hippocampus of APOE3 and APOE4 mice, both in the absence and in the presence of doxorubicin treatment. Unexposed APOE4 mice had a smaller hippocampus bilaterally compared to unexposed APOE3 mice, consistent with human imaging data of APOE4 control individuals (Reiman et al. 1998 ). After we exposed mice to doxorubicin, we found that the hippocampus and frontal cortex volumes were significantly impacted in size in both APOE3 and APOE4, but the changes were more severe in the APOE4 mice. These data demonstrate that doxorubicin may have a more significant Fig. 4 Effects of APOE genotype on ex vivo brain MRI. Voxel-based morphometry t test analyses of brains of 5 to 6-month-old control female APOE3 mice (n = 6) and APOE4 mice (n = 6) mice (a, b) or doxorubicintreated APOE3 mice (n = 5) and doxorubicin-treated APOE4 mice (n = 6) (c, d). Maximum intensity projection of the VBM results in sagittal, coronal, and axial slices and the design of the matrix for the study comparing control APOE3 versus control APOE4 mouse brains (a) or doxorubicin-treated APOE3 versus doxorubicin-treated APOE4 mice (c). Colored overlays corresponding to panels a and c on a co-registered template image showing the location of significant clusters in control APOE3 versus control APOE4 mouse brains (b) or doxorubicin-treated APOE3 versus doxorubicin-treated APOE4 mice (d). The color bar shows the t values of the statistical analyses. VBM performed across the entire brain revealed significantly more GM, defined by red areas (p < 0.01) impact on the hippocampus of individuals with an APOE4 allele than those with an APOE3 allele. The mammalian hippocampus is one of the few areas within the central nervous system where neurogenesis may occur throughout the lifespan of the animal (Bruel-Jungerman et al. 2007; Spalding et al. 2013) . Administration of cytotoxic agents (e.g., doxorubicin) may directly disrupt neurogenesis in the rodent hippocampus and impair performance on measures of spatial learning and memory (Lucassen 2016) . Since hippocampal volume decreases with aging, it is possible that differences between APOE genotypes may be more pronounced in older animals than those observed in the current study performed on young mice; we are actively investigating this possibility.
Behavioral tests in doxorubicin-treated APOE4 mice showed impaired spatial learning via the Barnes maze, correlating with the observed significant alterations in gray matter in the hippocampus. Unexposed APOE4 mice also showed deficits in the Barnes maze compared to unexposed APOE3 mice but to a lesser degree (Di Battista et al. 2016; Rodriguez et al. 2013) , consistent with our finding of smaller hippocampal volumes in unexposed APOE4 mice. Other behaviors, such as motor control, reward-seeking behavior, and visual acuity, were not measured through the behavioral tests administered. Future behavioral assessments could determine how well each of the VBM findings in our mouse model correlate with the neurological effects of chemotherapeutics. They also Fig. 5 Effects of doxorubicin treatment on ex vivo brain MRI. Voxelbased morphometry analyses of 3-D anatomical MR images of doxorubicin-treated APOE3 and APOE4 mice versus control APOE3 and APOE4 mice, respectively. Maximum intensity projection and pseudo-colorized images of F test clusters depicting regional brain differences between control versus doxorubicin-treated APOE3 mouse brains (a, c), and control versus doxorubicin-treated APOE4 mouse brains (b, d). Maximal differences in GM volumes using SPMMouse are shown in red color (p < 0.03) suggest that VBM can potentially be applied as an objective imaging biomarker of cancer-related cognitive decline in humans for improved diagnosis, prognosis, and treatment. Future research directions include investigating the utility of MRI to detect functional and metabolic alterations in our mouse model of cancer-related cognitive decline, which might enhance the sensitivity of non-invasive imaging in the diagnosis of this disorder.
The human APOE knock-in mouse model has contributed to our understanding of the effects of the APOE genotype on normal brain function and its effects on neurodegenerative processes (Sullivan et al. 2004 ). We observed greatly impaired spatial learning in the doxorubicin-treated APOE4 mice compared to the APOE3 mice; indeed, the APOE4 mice showed minimal learning over four training days. Control APOE4 mice, both in the current and in prior studies, have reduced spatial learning compared to APOE3 mice (Bour et al. 2008; Rodriguez et al. 2013 ), but not of the magnitude seen after exposure to chemotherapy. This is consistent with the differences seen in brain structure and function of APOE4 human subjects (Caselli et al. 2004; Filippini et al. 2009 ). In addition, APOE4 mice show decreased dendritic complexity (Dumanis et al. 2013; Rodriguez et al. 2013) , and increased inflammation in response to amyloid pathology (Rodriguez et al. 2014) and other inflammatory stimuli (Zhu et al. 2012) . APOE (Gafencu et al. 2007 ) and APOE-derived peptides (Christensen et al. 2011 ) have been linked to regulation of inflammatory pathways, which may have a role in the mechanism underlying cognitive-related cognitive decline. APOE is also associated with brain plasticity, and the APOE4 genotype may confer an increased susceptibility to damage from chemotherapeutic agents as a result of altered neuroplasticity (Laws et al. 2002; Nathoo et al. 2003 ). Chemotherapy appears to accelerate aging, and shares inflammatory and plasticity pathways with aging (Mandelblatt et al. 2014a ). Thus, the preclinical human APOE knock-in mouse model that we have developed recapitulates human cancer-related cognitive decline in its clinical manifestations and structural features. For these reasons, this novel genetic preclinical model appears to be a valid and relevant preclinical platform to study the mechanisms of cognitive impairment at the intersection of aging, cancer, and genetic risk for neurodegeneration.
The major strengths of this properly powered in vivo study include the integration of doxorubicin exposure with the use of both longitudinal behavioral analyses and ex vivo brain structure assessment by VBM in the context of different human APOE genotypes. There are several caveats that should, however, be considered in evaluating our results. First, while single exposures to chemotherapy are common in preclinical models (Reiriz et al. 2006; Yadin et al. 1983; Yanovski et al. 1989 ), it will be important to test repeated doses of doxorubicin treatment to determine whether that paradigm confers increased risk of cancer-related cognitive decline. It will also be informative to assess the effects of additional treatments commonly used in the clinic, such as hormonal therapy, which exhibits independent effects on the brain. Second, with regard to neurological performance, additional behavioral assays should be used in subsequent studies to define which cognitive domains are best suited for the analysis of specific regional brain impairments, such as attentional components that are affected in humans with cancer-related cognitive decline (Winocur et al. 2018 ). Third, tumor-naive mice were used in order to reduce variability due to tumor burden and associated morbidity, which could affect the capability of the animals to complete tasks. Since cognitive impairment has been noted even before treatment in human cancer populations (Jansen et al. 2011; Wefel et al. 2004 ), it will be important to repeat our experiments in mice with cancer. Finally, these studies were performed on young animals for a proof-of-concept, and there is a clear need to assess the impact of aging on behavior and brain biology following chemotherapy.
Overall, we report poorer cognitive behavior as well as altered hippocampal and cortical volumes in chemotherapy-treated APOE4 mice compared to APOE3 mice and unexposed controls. These results are consistent with clinical studies of APOE4 humans showing an increased risk for cognitive impairment after cancer chemotherapy. By generating the rational basis for the use of APOE status and age to inform treatment decision-making and survivorship care surveillance, this mouse model has direct implications for translation into clinical care in the growing population of cancer patients and survivors.
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